| Gender | Male/Female | 13/6 |
| Age (year) | Mean ± SD | 66.2 ± 10.1 |
| Range | 44 - 86 | |
| ECOG-PS | 0/1 | 19/0 |
| Surgery | Lobectomy | 19 |
| Histology | Adenocarcinoma | 17 |
| Squamous cell carcinoma | 2 | |
| Pathological stage | IIA | 2 |
| IIIA | 9 | |
| IIIB | 3 | |
| IV | 5 | |
| Chemotherapy | Neoadjuvant therapy | 3 |
| Adjuvant therapy | 11 | |
| Intensive chemotherapy for recurrence | 5 | |
| Regimen | GEM + CBDCA | 13 |
| PTX + CBDCA | 3 | |
| DOC + CDDP | 2 | |
| DOC | 1 | |
| Planned cycles | 2/3/4 cycles | 8/3/8 |
| Received cycles | 2/3/4 cycles | 8/3/8 |
| Compliance | Dose reduction | 5/19 (26.3%) |
| Delayed | 1/19 (5.3%) | |
| Response evaluation | Partial response | 3 (37.5%, 3/8) |
| Stable disease | 5 (62.5%, 5/8) | |
| Toxicities | ≥Grade 3/4 | 14/19 (73.7%) |